Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleTreatment of Meige's syndrome with cannabidiol.
Author(s)Snider S.R, Consroe P.
Journal, Volume, IssueNeurology 1984;34(Suppl):147.
Major outcome(s)50% improvement in spasm severity and frequency

Cannabidiol (CBD) is the major nonpsychoactive cannabinoid in marijuana. The anticonvulsant properties of CBD were demonstrated in humans 5 years ago. Based on anecdotal reports of improvement of generalized dystonia with marijuana smoking, we decided to try CBD in a patient with severe cranial dystonia (Meige syndrome). The patient, a 42-year-old man, first developed mild blepharospasm 9 years ago. The abnormal movements gradually spread to the oromandibular and neck muscles and worsened to the point that the patient was unable to drive. Many drugs were tried, with disappointing results. CBD was initiated at 100 mg/day, in divided doses, and slowly increased over several weeks to 400 mg/day. Other drugs were kept the same. Spasm frequency, counted twice daily by a relative while the patient was either talking or driving, gradually decreased from 20 to 30 per min before CBD to 7 or 15 per min at a dosage of 400 mg/day. Examinations at weekly intervals using a standard rating scale confirmed at least 50 % improvement in spasm severity and frequency. Withdrawal of CBD for 24 hours resulted in reappearance of severe spasm at 25 to 30 per min. Side effects included dry mouth, transient morning headache, and slight sedation.

Duration (days)
ParticipantsA 42 year old Meige syndrome patient
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]